What Johnson & Johnson Stock Told You Before It Surged

Johnson & Johnson stock’s oncology engine and its steady guidance raises were on the record quarters before the price moved.

A Run That Matched Merck And More Than Tripled The S&P

Over the year from late July 2025, Johnson & Johnson (JNJ) stock climbed about 61%, from roughly $165 to about $266, and now sits near the top of its 52-week range. That is more than triple the S&P 500’s roughly 17% over the same stretch. Among large-cap pharma peers, only Merck (MRK) kept pace, also up about 61%, while Eli Lilly (LLY) rose about 50% and Pfizer (PFE) about 6%. So for anyone who watched it run, the question is simple: was any of this legible before the price caught up?

The Oncology Engine And A Proposed Talc Resolution

Start with what the surge was actually about. By its fiscal Q2 2026 report, the company raised its full-year 2026 outlook and said it is on track to pass $100 billion in annual revenue for the first time in its history, with the midpoint of guidance near $101 billion and adjusted operational earnings guided to $11.50 to $11.65 a share. The engine was Innovative Medicine, up 6.8% operationally and led by oncology, where DARZALEX cleared $4 billion, up about 18%; in immunology, TREMFYA grew 71%. A second overhang began to lift as well: as the window closed, the company announced a proposed comprehensive resolution of its ovarian talc litigation, conditioned on participation from at least 95% of remaining claims, moving to resolve a long-running overhang.

The Guidance Was Being Raised A Year Early

Here is the tell. Management did not spring this on anyone. By the company’s own account a full year earlier, at its fiscal Q2 2025 report in mid-July 2025, it had already raised full-year 2025 sales guidance by $2 billion and lifted its earnings target to $10.85 a share. Oncology was growing 22% operationally even then, and management was on record targeting the number-one spot in oncology by 2030 with more than $50 billion in sales. The direction of travel was set and stated; the price simply had not moved yet.

The Same Products Were Named Quarters Before

The specific drivers were named early too. TREMFYA, up 71% by fiscal Q2 2026, was already growing 30% a year earlier and flagged for its inflammatory-bowel expansion. A bladder-cancer therapy was in FDA priority review by mid-2025, and its application had been filed as far back as the fiscal Q4 2024 report in January 2025. Over the same span the count of billion-dollar platforms rose from 26 to 28. A reader tracking the pipeline was watching the same names that later drove the run.

Why The Backward-Looking Numbers Gave No Tell

The catch is that the signal was in the forward framing, not the rear-view mirror. As of its fiscal Q1 2025 results, one quarter before that guidance raise, trailing revenue was $89.33 billion, up just 4.3% year over year and roughly in line with its own three-year pace, while net margin sat at 24%, well below its three-year peak of 45%. The options market gave no warning either: with implied volatility in the 44th percentile of its one-year range by mid-July 2025, traders were positioned for a move no larger than normal, in either direction. Anyone waiting for the trailing numbers to confirm the story would have waited past the run.

So Were The Signs Really Actionable?

Honestly, the signs were legible but not easy. The raised guidance, the 22% oncology growth and the named launches were all on the record before the move, so this was not pure hindsight. Acting on them, though, meant trusting forward guidance over steady trailing revenue, a compressed margin and a live talc overhang that was still producing verdicts against the company. That is a judgment call, not a certainty, and one reason some readers prefer the health-care sector (XLV) to any single name. The forward-looking version of this same setup is a screen for names where rising guidance meets improving momentum, and JNJ’s own record here shows why that pairing is worth watching before the price agrees.

Reading Guidance Well Is A Skill, Not A Portfolio

Catching one well-signaled winner is a skill worth having; turning it into lasting wealth is a different problem. A single stock, even one that told its story in advance, still carries the full weight of its own risks, from litigation to a launch that stalls. A rules-based portfolio spreads that judgment across many positions and re-balances on evidence rather than conviction. If you want the system rather than the single bet, the HQ Portfolio applies this discipline across a whole book. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.